GlaxoSmithKline PLC (LSE:GSK) - Share price


Stock Report

GlaxoSmithKline PLC GSK

Last Price
GBX1,647.20

Day Change
10.60|0.65%

As of 21/01/2022
18:29:15 GMT | GBX
Minimum 15 Minutes Delay.

Last Close1,636.60p
Day Range1,620.80 - 1,653.80
Mkt Cap82.88Bil
52-Wk Range1,190.80 - 1,653.80
Yield %4.86
ISINGB0009252882
Volume10,986,815
P/E19.34
P/S0.02
P/CF0.10

Share Price

Total Returns 21/01/2022

 Chg (%)  
More ...
GlaxoSmithKline PLC2.45 
FTSE 100 TR GBP2.82
 
Financials
201820192020
More ...
Income Statement
Turnover30,821.0033,754.0034,099.00
Operating Profit7,060.006,292.006,224.00
Net Profit4,046.005,268.006,388.00
Reported EPS72.9092.60114.10
Balance Sheet
Current Assets16,274.0018,618.0020,141.00
Non Current Assets41,139.0060,201.0060,184.00
Total Assets58,066.0079,692.0080,431.00
Current Liabilities22,491.0024,050.0022,148.00
Total Liabilities54,394.0061,335.0059,623.00
Total Equity3,672.0018,357.0020,808.00
Cash Flow
Operating Cash Flow9,747.009,532.0010,096.00
Net Change in Cash479.00826.00470.00

Regulatory News

DateAuthor Headline
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete
10/07/2019Emma Simon Dividend Shares to Fund My Retirement
Investor Views: Private investor Gurmit Dhendsa is running his own share portfolio rather than rely on a pension manager
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
22/07/2021PurchaseDr. Hal V Barron19.622,36146,311.00
13/07/2021DDr. Hal V Barron20.222,45049,543.00
13/07/2021DMs. Emma N. Walmsley1,441.972,80040,375.00
12/07/2021DDr. Hal V Barron19.991,08021,584.00

Company Profile

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Sector

Drug Manufacturers - General

Index

FTSE 100 , FTSE 350 , FTSE All Share , FTSE Eurotop 100 , FTSE Eurotop 300

Next Event 09/02/2022

Final Results
Ratios
Comp
More ...
PER (E)18.87
Div Yld (E)4.98
PEG (E)3.60
ROCE13.42
Op Mrgn0.18
EPS Grwth0.06
Dividends
PreviousLatest
More ...
Record Date20/08/2119/11/21
Ex-Div19/08/2118/11/21
Paid07/10/2113/01/22
Amnt19.0019.00
Directors
More ...
Non-Executive DirectorMs. Lynn Laverty Elsenhans
Executive Director, Chief Scientific Officer and President, RandDDr. Hal V Barron
Non-Executive DirectorMs. Judy C. Lewent
Non-Executive DirectorDr. Laurie H. Glimcher, M.D.
Non-Executive Director, ChairmanSir Jonathan Richard Symonds, CBE
Non-Executive Director, Senior Independent DirectorMr. Manvinder Singh Banga
Non-Executive DirectorMr. Urs Rohner
Non-Executive DirectorDr. Vivienne Cox, CBE
Non-Executive DirectorMr. Charles A. Bancroft
Company SecretaryMrs. Victoria Anne Whyte
Executive Director, Chief Financial OfficerMr. Iain J Mackay
Executive Director, Chief Executive OfficerMs. Emma N. Walmsley
Non-Executive DirectorDr. Jesse Goodman
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.